Find Search

Other Information

Quest Vitamins LTD,
8 Venture Way,
Aston Science Park,
B7 4AP.

Tel: 0121 359 0056
Fax: 0121 359 0313
Registered in England No. 2530437

Benign Prostatic Hyperplasia (BPH)


This non-infectious, non-malignant enlargement of the prostate gland occurs in 50 to 60% of men, ages 40 to 59. An increase in prostatic concentrations of potent androgen, a derivative of testosterone, is most likely the cause. Other hormone levels are also elevated, including prolactin, oestradiol, and follicle-stimulating hormone.

The enlargement of the prostate may lead to urethra obstruction. Symptoms of BPH include bladder outlet obstruction (hesitancy, increased urinary frequency, waking at night to urinate, etc.); and an enlarged, non-tender prostate gland.


Panax Ginseng (4)
Nettle (5)
Saw Palmetto (6)


Bee Pollen
Evening Primrose Oil (2)
Flax Seed Oil (2)
Glutamic Acid (1)
Zinc (3)


1. Damrau F. Benign prostatic hypertrophy: amino acid therapy for symptomatic relief. J Am Geriatr Soc 1962;10:426-30.
2. Hart JP and Cooper WL. Vitamin F in the treatment of Prostatic Hyperplasia. Lee Foundation for Nutritional Research, Report #1. Milwaukee, Wisconsin:1941.
3. Fahim M, Fahim Z, and Harman J. Zinc treatment for the reduction of hyperplasia of the prostate. Fed Proc 1976; 35:361.
4. Saito Y. Diagnosis and treatment of chronic prostatitis with special reference to experience with Cernilton. Clin Exp Med 1967; 44:387-93.
5. ESCOP monographs. Fascicule 2: Urticae radix. Exeter, UK: European Scientific Cooperative on Phytotherapy, 1997: 4.
6. Carraro J, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29(4): 231-240, 1996.


Print this page